Abstract: Non-steroidal compounds which are high affinity, high specificity ligand antagonists for the androgen receptor are disclosed. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by the androgen receptor and for treating patients requiring androgen receptor antagonist therapy.
October 21, 1993
Date of Patent:
October 14, 1997
Ligand Pharmaceuticals Incorporated
Todd K. Jones, Lawrence G. Hamann, Luc Farmer, Michael G. Johnson, Mark E. Goldman
Abstract: A percutaneous absorption preparation comprising a support and, formed on one side thereof, a plaster layer comprising a pressure-sensitive adhesive and tulobuterol in an amount not lower than its saturation solubility in the pressure-sensitive adhesive, the tulobuterol contained in the plaster layer consisting of dissolved tulobuterol and crystalline tulobuterol with the ratio of the content of the crystalline tulobuterol to that of the dissolved tulobuterol being from 0.1 to 10.
Abstract: A magnesium-containing analgesic composition used for treating migraine headaches and methods for using the same are described herein. The composition comprises an analgesic, a magnesium salt and an effervescing agent and is admixed with or dissolved in water prior to ingestion. The symptoms of migraine headache intended to be alleviated include nausea, unilateral pain, dizziness, pulsatile pain, worsening of pain by light physical activity, photophobia and phonophobia.
Abstract: A method for the topical treatment of herpes virus infections of the skin and mucous membranes is disclosed- This method uses a topical preparation comprising an anti-vital drug in combination with a potentiating drug which is an anti-inflammatory or an anti-oxidant drug. A preferred preparation includes zinc pentosan polysulphate in combination with bufexamac.
Abstract: This invention relates to structurally novel acyclic tocotrienol analogs, which are useful for cholesterol/lipid lowering in cases of hypercholesterolemia and hyperlipidemia, and for atherosclerosis. Also provided are pharmaceutical compositions and a method of use employing those compositions.
Abstract: A quinone derivative useful in the treatment of hepatic diseases defined by the general formula: ##STR1## where X and Y may be the same or different from each other and are each a hydroxyl group, a group represented by the formula --(--OCH.sub.2 --).sub.n --OR.sup.6, wherein n is 0 or 1 and R.sup.6 is a lower alkyl group, or an acyl group.
Abstract: The present invention relates to topical aromatic releasing compositions substantially free from petrolatum and containing one or more volatile aromatic compounds selected from the group consisting of menthol, camphor and eucalyptus oil and mixtures thereof. In further embodiments, these compositions contain one or more topical actives, and are also useful for providing relief from symptoms associated with respiratory disorders.
Abstract: A fortified quaternary ammonium compound with and without dual synergistic phenols is provided for disinfection and sanitization. One formula consists of dual chain quaternary ammonium chloride (N-alkyl dimethylethylbenzyl ammonium chloride and N-alkyl dimethylbenzyl ammonium chloride), ortho phenyl phenol, para tertiary amyl phenol, citric or acetic acid, sodium citrate, isopropyl or ethyl alcohol, triethanol amine-HCl and water in the following proportions 50.00 to 0.50 grams, 1.00 to 0.08 grams, 1.00 to 0.08 grams, 0.50 to 0.05 grams, 0.25 to 0.025 grams, 14.00 to 1.40 grams, 5.00 to 1.00 grams, 28.25 to 96.865 grams. The formula for environmentally protected uses consists of dual chain quaternary ammonium chloride (N-alkyl dimethylethylbenzyl ammonium chloride and N-alkyl dimethylbenzyl ammonium chloride), citric or acetic acid, sodium citrate, isopropyl or ethyl alcohol, triethanol amine-HCl and water in the following proportions: 50.00 to 0.50 grams, 0.50 to 0.05 grams, 0.25 to 0.025 grams, 14.00 to 1.
Abstract: A sterilising composition of antibacterial and antimycotic activity possessing considerable stability with time, comprising glutaraldehyde, an alkyl-, aryl- or halogen-substituted phenol, a non-ionic surface-active agent and preferably an alkanol of 2-5 carbon atoms, in an aqueous vehicle, at a pH of between 3.5 and 5.5.
Abstract: A solid, storage-stable, germicidal, pre-iodine composition comprises in dry admixture with each other a solid oxy-compound of iodine, a solid reducing agent for the oxy-compound of iodine, and a solid desiccant used in amount sufficient to combine during the storage cycle of the composition with ambient and/or endogenous water. The oxy-compounds of iodine are iodic acid, iodine pentoxide, potassium iodate and sodium iodate. Preferred reducing agents are ascorbic acid, dihydroxy fumaric acid, the thiol sugars and cysteine. A preferred combination desiccant and iodine solvating agent is polyvinyl pyrrollidone having a molecular weight of from 10,000 to 1,000,000.The composition is storage-stable for an indefinite period. Upon the addition of water, the oxy-compound of iodine is reduced to nascent iodine, which, in application, serves its well-known germicidal function.
Abstract: A method of treating a subject in cardiac arrest, comprises blocking the descending aorta of the subject and then perfusing the aortic arch of the subject with a protective solution. The protective solution is one capable of delivering oxygen to the heart of said subject, such as a perfluorochemical blood substitute. Following perfusion, spontaneous circulation is restored.In an improved embodiment of the foregoing, a vasoconstrictor such as epinephrine is administered concurrently with the perfusing step in an amount effective to enhance coronary perfusion with said protective solution.
September 30, 1991
Date of Patent:
June 1, 1993
The University of North Carolina at Chapel Hill
Abstract: A method for effecting oncolysis, regression, and control of malignant neoplasms in humans and other mammals without adverse effects on normal body cells is described. An ATP-availability depressor may be combined with a defined nutritional regimen, a fatty acid blocker, an amino acid blocker, a lactate export blocker, or any combination thereof.
Abstract: A method of producing oncolysis and regression of malignant tumors and other malignant conditions without adverse effects on normal body cells is described. A calorically and compositionally defined nutritional regimen providing a minimum of amino acids and fatty acids and a maximum of carbohydrates is administered concurrently with a drug regimen of an agent or agents that uncouple oxidative phosphorylation, most preferably 2,4-dinitrophenol.
Abstract: An improved method is described for producing oncolysis, including regression of malignant tumors or other malignant conditions, without adverse effects upon normal body cells. In addition to a calorically and compositionally defined nutritional regimen providing a minimum of amino acids and fatty acids and a maximum of carbohydrate, administered concurrently with a drug regimen of an agent or agents that uncouple oxidative phosphorylation (most preferably 2,4-dinitrophenol), there is also concurrently administered a selected amount of a substantially non-toxic fatty acid oxidation inhibitor capable of effectively lowering the mitochondrial .beta.-oxidation rate of fatty acids.
Abstract: A synthetic detergent bar is provided containing hydroquinone as a skin bleaching agent. The bar is maintained at a pH of between about 4 and 7 and includes a compressed mixture of a synthetic anionic detergent such as sodium cocoyl isethionate, sodium lauryl sulfoacetate and sodium methyl cocoyl tourate; hydroquinone, a stabilizer for said hydroquinone such as tertiary butyl hydroquinone, water, a buffer which maintains the pH of the bar at about 4 to about 7 and excipients such as waxes, paraffin, dextrin and starches. Because of the maintenance of low pH and the presence of a stabilizer, hydroquinone is not oxidized and thus the bar is characterized by an extended shelf life.